Dexa Medica, one of Indonesia’s largest pharmaceutical companies, has consistently used its sophisticated research capabilities to prioritize Indonesia’s public health needs. Its motto — to use expertise for the promotion of health — is a natural consequence of this long-standing commitment to improving healthcare for all. The company and its management team are guided by its four core principles: honesty, trust, dedication, and commitment.
Dexa Medica was founded in Palembang (South Sumatera, Indonesia) in 1969 by the late Lieutenant Colonel apt. Drs. Rudy Soetikno, a low-profile young pharmacist in the Health and Medical Corps of the Indonesian Army. He was inspired by the scarce supply of medicine in Indonesia. Drs. Soetikno’s devotion to his country and his pharmaceutical expertise had uniquely positioned him to supply medicine — which turned out to be his calling in life.
He began producing basic tablets in a small pharmacy that they jointly owned with some partners. Since then, Dexa Medica has grown into one of Indonesia’s largest pharma company in Indonesia. Drs. Soetikno and his excellent team have fostered an environment of mutual respect, teamwork, and innovation for the company.
Vision & Mission
To be a leading company dedicated to providing significant added values for the benefit of our customers, business partners and stakeholders through effective, efficient, and continuous operations to achieve “health for all” nationwide, as well as regionally and globally.
To establish our pharmaceutical capacities and competencies in enhancing the quality of our healthcare system through:
The name Dexa is derived from the Greek word “Deca” (δέκα), which means 10 — a universal symbol of perfection. The name reflects the company’s philosophy, which aspires, even today, to continue the long tradition of perfectionism. For more than five decades, Dexa has upheld three core values:
A commitment to provide the best possible value to our customers while exercising prudence and emphasizing compliance at all times.
A dedication to working with professionalism, with an emphasis on honesty and integrity.
Fostering a nurturing intent, by always seeking to understand and respect one another.
At Dexa, activities are focused on four core competencies:
Mobilise resources to deliver the best possible products in the most efficient manner.
Facilitate opportunities to do whatever is needed to provide patients with superior, distinctive, and differentiated products.
Select and maintain the right partners for synergistic improvements.
Anticipate changes and proactively update plans to take advantage of the impending changes in the business and the industry.
Dexa’s business is focused on two main aspects: manufacturing and R&D. We manufacture our products in three main factories:
for solid and cephalosporin production
for API Production – Discovery, Research, and Development
for solid production high volume products
Dexa has made consistent, liberal re-investments into its core business, continually developing highly innovative pharmaceutical products through meticulous research and development. It operates an advanced, integrated research facility, the Dexa Development Center (DDC) in Jababeka, Cikarang. DDC is specifically designed to accommodate up to 250 scientists so that it can produce as many as 30 dossiers (CTDs and ACTD) every year. Its activities include conventional formulation and the development of New Drug Delivery System (NDDS).
Since 2005, the company’s research wing Dexa Laboratories of Biomolecular Sciences (DLBS) has also been discovering active ingredients that are indigenously found in Indonesia. These rare ingredients are subsequently utilized in herbal medicines manufactured by Dexa Group and offered to the people at an affordable rate, keeping with the company’s commitment to improving healthcare for all. DLBS uses life sources for organisms — such as plants, animals, and microbes — to improve people’s quality of life. It is still home to some of the world’s most talented scientists and pharmacists, hundreds of them from Indonesia. It also collaborates with and trains farmers to produce high-quality, standardized, natural ingredients.
PT Dexa Medica made a huge contribution in the development of Indonesian Indigenous Modern Medicines (OMAI). OMAI is medicine extracted from Indonesia’s natural wealth and developed with modern technology. OMAI consists of Standardized Herbal Medicines (OHT) that have passed pre-clinical trials, and phytopharmaca (fitofarmaka) that have passed clinical trials. Currently, 37 of 97 registered OHT and 28 of 31 registered phytopharmaca are produced by Dexa.
PT Dexa Medica is the first private company in Indonesia to produce Obat Generik Berlogo/OGB (nonbranded generics), and one of only five pharmaceutical companies to have received the Good Manufacturing Practices certification (Cara Pembuatan Obat yang Baik/CPOB).
OGBdexa has launched more than 50 new medicines in the last 5 years, and has a portfolio of more than 187 medicines. To meet the OGB market demand, Dexa Medica produces more than 1 billion tablets, vials, and ampoules of medicine every year. OGBdexa is available across Indonesia, in more than 21.000 pharmacies, hospitals, health offices, and community health clinics. As part of the Indonesian national health insurance system — Jaminan Kesehatan Nasional (JKN) — OGBdexa plays a crucial role in providing medicines for the 262 million beneficiaries of JKN.